A novel nasal powder formulation of glucagon: toxicology studies in animal models

BACKGROUND: Glucagon nasal powder (GNP), a novel intranasal formulation of glucagon being developed to treat insulin-induced severe hypoglycemia, contains synthetic glucagon (10 % w/w), beta-cyclodextrin, and dodecylphosphocholine. The safety of this formulation was evaluated in four studies in anim...

Descripción completa

Detalles Bibliográficos
Autores principales: Reno, Frederick E., Normand, Patrick, McInally, Kevin, Silo, Sherwin, Stotland, Patricia, Triest, Myriam, Carballo, Dolores, Piché, Claude
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621930/
https://www.ncbi.nlm.nih.gov/pubmed/26502880
http://dx.doi.org/10.1186/s40360-015-0026-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4621930/
https://www.ncbi.nlm.nih.gov/pubmed/26502880
http://dx.doi.org/10.1186/s40360-015-0026-9

Ejemplares similares